heavy chains are synthesized, they associate with/~2m inefficiently, if at all. Previous studies have demonstrated that mutant HLA-A2 heavy chains that fail to associate with ~2rn neither mature to the cell surface nor express alloantigenic determinants (10) .
Members of a third class ~.ppear to express normal amounts of cell-surface HLA-A2 molecules that display reduced reactivity with the selecting antibody, but normal or near-normal reactivities with ~ome other HLA-A2-specific monoclonal antibodies and human alloantisera. Such properties indicated their potential utility in defining the BB7.2 epitope, as well as in probing the relationships among various class I antigen serologic and cellular recogniti~Jn determinants.
Structural studies of the HLA-A2 heavy chains derived from two of these variants, 8.18.1 and 8.21.1, are described in the present study. These variants are distinguishable both from TS-1 and from each other by their relative reactivities with the selecting antibody BB7.2, as well as with a second HLA-A2-specific rnonoclonal antibody, PA2.1. In addition, HLA-A2 heavy chains synthesized by 8.18 .1 are the equivalent of a single charge more basic than those of T5-1, whereas those synthesized by 8.21 .1 are the equivalent of a single charge more acidic. 2 Comparative tryptic peptide analyses presented here indicate that these heavy chains carry distinct mutations in the same peptide. We conclude that residues within this short segment of the polypeptide contribute to an HLA-A2-specific serological determinant.
Materials and Methods

Cell Lines and Metabolic Labeling.
The human B lymphoblastoid cell line T5-1 (HLA-A1, -A2, -BS, -B27, and -Cwl) and the HLA-A2 variant clones 8.18.1 and 8.21.1 derived from T5-1 by mutagenesis followed by immunoselection 2 were cultured as described (10) . [4,5- 
t).
Purification ofRadiolabeled HLA-A2 Heavy Chains. This procedure has been described in detail elsewhere (11) . Briefly, detergent lysates were prepared from labeled cells and immunoprecipitated with the HLA-A2-specific mouse monoclonal antibody PA2.1 (12) . After denaturation, immunoprecipitated species were then subjected to a second round of immunoprecipitation, this time using a rabbit anti-HLA heavy chain serum (13) . The resulting HLA heavy chain preparations were of >95% purity, as assessed sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fluorography. Yields of HLA-A2 heavy chain radioactivity as a percentage of total incorporation into cells were typically 0.05% for T5-1, half that for 8.18.1, and half again for 8.2 I. 1, because of reduced reactivities with the PA2.1 antibody.
Peptide Mapping. 3H-, 14C-, or 35S-labeled HLA-A2 heavy chain preparations were combined, reduced and alkylated, and digested with trypsin as described (11) . Peptide mapping was by reverse-phase high-pressure liquid chromatography (HPLC) on a 4-ram × 25-cm Zorbax C-8 column (Dupont Instruments, Wilmington, DE), using a 0-30% concave gradient of acetonitrile in 10 mM ammonium acetate (pH 6.5) as described (11) . Radioactivity was determined by liquid scintillation counting.
Microsequence Analysis. This was performed on a Beckman liquid-phase sequencer 890C
(.Beckman Instruments, Inc., Fullerton, CA) as described (11, 14) .
Results
Strategy.
To assess the relatedness of the HLA-A2 heavy chains synthesized by the parent cell line T5-1 and its immunoselected variants, cells were metabolically labeled STRUCTURE OF IMMUNOSELECT£D HLA-A2 MUTANTS with either aH or 14C amino acids, and purified heavy chains were compared by double-label tryptic peptide analysis. Crucial to such an analysis is the ability to compare most, if not all, tryptic peptides in the molecule. 90% of the amino acid sequence of the 271 residue papain solubilized HLA A2 molecule (5), as well as 32 residues of the carboxy-terminal, intracetlular portion have been determined (15) . Thus, most tryptic peptides can be predicted from the known sequence. Tentative assignments for the remaining residues based upon homology with HLA-A28 (96% homologous) or with HLA-B7 (86% homologous) when both HLA-A2 and -A28 are unassigned, predict 41 tryptic peptides. Although a combination of radioactive lysine and arginine should label all but the carboxy-terminal peptide, this approach could not be taken because of an inalaility to incorporate sufficient amounts of radiolabeled arginine. The alternative adopted involved metabolic labeling with five different amino acids, which would label overlapping sets of tryptic peptides encompassing virtually the entire molecule. The amino acids used, lysine (K), leucine (L), serine (S), proline (P), and alanine (A), were predicted to label 11, 16, 11, 11, and 17 peptides, respectively, covering 98% of the detergent solubilized molecule. These numbers must be regarded with caution pending definitive assignment at the remaining residues of the HLA-A2 sequence. Previous work (1 I) has indicated that peptide mapping by reverse-phase HPLC is a sensitive method with which to compare most tryptic peptides in the molecule. Thus, in the present study, radiolabeled HLA-A2 heavy chains purified from parent and variant cell lines were combined, reduced and alkylated, and digested with trypsin, and the resulting fragments were resolved and compared by HPLC. 8.18 . l. Lysine-, leucine-, serine-, proline-, and alanine-containing tryptic peptides derived from T5-1 and 8.18.1 are compared in Figs. I-5, respectively. For the purpose of discussion, individual peaks will be referred to based upon the amino acid label • 30 ,~
.2o
.io
(-) vs.
[aH]leucine-labeled 8.18.l (...). Note that the acetonitrile gradient used is different from that in other comparisons, as described (11) . Note that the solid arrow at tube S141 marks a shoulder sometimes, but not always resolved from that at S138 (see Fig. 8 , for example). The factors influencing this resolution are not cell line specific. and peak fraction number of the peptide. Thus, the flow-through peak in the serine map would be referred to as peak $6. It is immediately apparent that these molecules are highly homologous. No differences can be observed in the lysine-, leucine-, proline-, or alanine-containing tryptic peptides. However, multiple differences in the [aH]serine vs.
[14C]serine comparison are detected (Fig. 3) .
Differences in the serine map can be grouped into two categories based upon a control comparison of [3H]serine vs.
[14C]serine-labeled T5-1 HLA-A2, which is presented in Fig. 6 . Thus, differences in Fig. 3 peaks $79, $82, S122, S130, and the shoulder at S141 (solid arrows) are also evident in the control comparison, whereas those in peaks S 126 and S 135 (open arrows) are not. Those differences present in the control comparison have been shown previously to result from the metabolic conversion of radiolabeled serine to glycine with preferential loss of 3H label during the interconversion (11) . This is the only interconversion that has been detected.
Relative to the control comparison, the Fig. 3 comparison differs by the loss of 3H radioactivity at peak S126 and the gain of 3H radioactivity at peak S135. This sugIgested the possibility that TS-1 peptide S126 was altered in 8.18.1, and hence ehlted later in the peptide profile, at S 135. This interpretation was confirmed and the difference peptide was identified by the following experiments. Peptide S126 was isolated from [3H]serine-labeled T5-1 HLA-A2 and subjected to 12 cycles of automated Edman degradation. Radioactivity was released at cycle 8 ( Fig. 7 A) . Hydrolysis of the peptide followed by analysis by thin-layer chromatography indicated that virtually all of the radioactivity in this peptide migrated as serine and not glycine; thus, it could be concluded that S126 had a serine residue at position 8. Sequence analysis of peak S 135 from double-label comparisons of [3H]serine-labeled 8.18.1 and [t4C]serinelabeled T5-I HLA-A2 yielded both 3H and 1~C radioactivity at cycle 1, and 3H radioactivity at cycle 8 (Figs. 7 B and C). We interpret this as a mixture of a peptide common to both cell lines with the 8.18.1 counterpart of T5-1 peptide S126. A comparison of these partial sequences with those of all predicted serine-containing tryptic peptides (Table I) [3H]serine-labeled T5-1 (-• .). Differences are denoted by solid arrows. That at S141 is barely resolved from the peak at S138 in this instance, but has been resolved on other occasions. peptide in peak S135 spanned residues 132-144. Because the difference peptide was observed in neither the proline nor the alanine maps (Figs. 4 and 5, respectively), and because the peptide spanning residues 244-256 contains both of these residues (Table  I) , it was most likely that peptide S126 spanned residues 98-108 of the HLA-A2 heavy chain. Because identification of the difference peptide rested on the determination of only a single amino acid, further partial sequence and compositional information was desirable for confirmation. The sequence of the T5-1 form of this peptide is predicted to be MYGCDVGSDWR; thus, it is unique in being the only tryptic peptide in the molecule that contains both methionine and cysteine. The presence of cysteine in the difference peptide was demonstrated by two lines of evidence. First, [14C]serine-labeled T5-1 HLA-A2 reduced and alkylated with iodoacetamide as usual was compared with [3H]serine-labeled T5-1 HLA-2 reduced and alkylated with iodoacetic acid. A difference in such a comparison would identify an alkylated peptide, and this was indeed observed for peak S 126. Furthermore, separate peptide maps of [aSS]cysteine-labeled T5-1 HLA-A2 and 8.18.1 HLA-A2 were performed. A T5-1 peak at fraction 126 was absent in 8.18.1, and a new peak in 8.18.1 appeared at fraction 135. Sequence analysis (Fig. 8) . All of the lateeluting peptides are displaced by about three fractions relative to previous comparisons. The T5-1 glycine peptides at fractions 125, 133, and 144 (solid arrows) are thus identical to Fig. 3 T5-1 peptides S121 and S130 and the shoulder at fraction 141, and the T5-1 serine peptides at fractions 129, 137, and 141 are identical to Fig. 3 T5-1 peptides S126, S134, and S138. It is clear from this comparison that the T5-1 peptide at fraction 129 (open arrow), corresponding to S126 in Fig. 3 , does not have a comigrating 8.21.1-derived counterpart. This indicates that 8.21.1 is altered in the same peptide as 8.18.1. However, the two mutations in this peptide appeared to be nonidentical, because the 8.21.1 form of the peptide was not evident, eluting somewhat later than its T5-1 counterpart, as was the 8.18.1 form.
To clarify this difference between the two mutants, it was of value to identify the 8.21.1 form of the difference peptide. It might not be observed in the Fig. 8 comparison because of altered solubility properties, poor elution off the column, the loss of a serine residue at position 8, or co-elution with higher-yield peptides. Some of these possibilities could be tested by choosing a different amino acid for labeling the peptide; methionine was an optimal choice because it is a relatively rare amino acid that labels the corresponding T5-1 peptide. A comparison of [3H]methionine-with [35S]methionine-labeled peptides is presented in Fig. 9 . The two cell lines clearly differ in that the T5-1 peptide at M126 has apparently shifted to M88 in 8. Discussion HLA-A2 mutants have been obtained by immunoselection using the HLA-A2-specific mouse monoclonal antibody BB7.2 plus complement. Two mutants that synthesize HLA-A2 molecules with reduced reactivity with the selecting antibody and with structurally altered HLA-A2 heavy chains have been analyzed in detail. Using double-label tryptic peptide mapping, we demonstrate that these two mutants have distinct alterations in the same tryptic peptide in the molecule. Although it is possible that other alterations in these molecules exist but have not been detected by the present analysis, the isolation of two mutants with alterations in the same peptide suggests strongly that the detected changes play crucial roles in determining the serologic properties of these molecules.
(open arrows). This
Available evidence suggests that the mutations do not induce gross structural alterations in these molecules. Thus, although reactivities with both the selecting antibody and the HLA-A2-specific monoclonal antibody PA2.1 are diminished, reactivities with a polyclonal HLA-A2-specific human alloantiserum are largely unaffected, and no effect at all has been observed with respect to the binding of the HLA-A2 and -B17-specific monoclonal antibody MA2.1 (16) and the HLA-A, -B, and -C-specific monoclonal antibody W6/32. 2 The determinants recognized by all such antibodies are highly sensitive to the conformation of the molecule. Furthermore, although the altered peptide is known to contain a cysteine involved in an intramolecular disulfide bond, the results of labelings with [35S]cysteine indicate that this residue has not changed in either mutant. It is therefore likely that a residue or residues in this peptide play a direct role in forming an HLA-A2-specific antigenic determinant.
Comparative primary structural analyses of three HLA molecules have indicated the presence of a few discrete segments that display relatively high variability, the most prominent of which span residues 65-80, 105-116, and 177-194. HLA-A2 and -A28 are highly cross-reactive, and only 10 amino acid differences have been detected between them (5). Five are in the first segment, two are in the second, and the remainder are highly conservative substitutions scattered throughout the molecule. The difference peptide defined in this study spans residues 98-108 and has the sequence MYGCDVGSDWR. HLA-A28 has an identical sequence, save for a W to G substitution at position 107. Because the monoclona[ antibody used for immunoselection reacts with HLA-A2 but not with HLA-A28, some of the residues that form the BB7.2 epitope should differ in HLA-A28. We suggest that W107 may therefore be a critical residue in forming the BB7.2 antigenic determinant. Although we do not know which residues are altered in mutants 8.18.1 and 8.21.1, we nevertheless can hazard a guess. The 8.18.1 HLA-A2 heavy chain is a single charge more basic than its wild-type counterpart, and the difference peptide has elution properties that indicate an increase in hydrophobicity. These and other pieces of evidence suggest the likelihood of a substitution of a neutral amino acid for an acidic one. Although two acidic residues exist in the wild-type form of the peptide, we suggest that D 106, which is within the previously defined variable segment and adjacent to W107, may have changed in 8.18.1. Conversely, because the 8.21.1 HLA-A2 heavy chain is a single charge more acidic than wild type, and the difference peptide in this case appears less hydrophobic, the substitution here may involve the gain of an acidic residue.
Although residues in this peptide are necessary for the complete expression of the BB7.2 and PA2.1 epitopes, they are certainly not sufficient. Neither antibody binds detectably to wild-type HLA-A2 heavy chains that are not associated with fl2m (13; P. Parham, personal communication), presumably because of the loss of native conformation (17) . Furthermore, preliminary results indicate that a third BB7.2-immunoselected mutant, 8.6.1, has an alteration in a peptide distant in the linear amino acid sequence from that described here, but nevertheless residing in the same domain of the HLA-A2 heavy chain (S. Taketani and M. S. Krangel, unpublished observations). Thus, other segments of the polypeptide in the second domain may take part directly in the BB7.2 epitope, or possibly stabilize the conformation of residues that are directly involved.
Histocompatibility antigens carry multiple serologically defined alloantigenic determinants. Blocking studies in both the murine and human systems have demonstrated the presence of spatially separate antibody binding sites on the same molecule (18-20). Although BB7.2, PA2.1, and MA2.1 all cross-block (8, 9) , their antigenic determinants are nevertheless distinct. The MA2.1 determinant is clearly different from those of PA2.1 and BB7.2 because it is also found on HLA-B17, and because mutants selected with BB7.2 are unaltered in their MA2.1 reactivity. On the other hand, the determinants recognized by BB7.2 and PA2.1 are nearly identical. Although neither antibody reacts with HLA-A28, both react with a presumed HLA-A28 variant cell line, IDF, and immunoselection ofT5-1 HLA-A2 mutants with BB7.2 results in an altered PA2.1 determinant. However, the different mutations that characterize 8.18.1 and 8.21.1 can distinguish these antibodies. Thus, comparative binding studies indicate that whereas PA2.1 has a higher affinity for 8.18.1 than for 8.21.1, this situation is reversed for BB7.2 (unpublished observations). The binding of these antibodies to HLA-A2 molecules may involve different contacts, possibly including some different residues, at the same site on the molecule.
Increasing evidence indicates that the determinants defined by serology may not be identical with those recognized by CTL. Thus, H-2K b mutants with gross alterations in CTL recognition properties have rather limited alterations in serological determinants (21, 22) . HLA-A2 structural variants that are not recognized by HLA-A2-restricted, influenza-virus-immune or HLA-A2-specific alloimmune CTL nevertheless have normal reactivities with alloantisera and monoclonal antibodies specific for HLA-A2 (11, 23, 24) . 3 Preliminary results indicate HLA-A2-specific alloimmune CTL recognition of immunoselected mutants 8.18.1, 8.21.1, and 8.6.1 may be largely or completely unaffected (C. Ware, personal communication). However, detailed analyses of the reactivities of a battery of HLA-A2-specific CTL clones will be required to more precisely address this question. It is anticipated that extensive primary structural comparisons of allelic products, the generation and analysis of many other variants with altered recognition properties, and ultimately, knowledge of the three-dimensional structure of the molecule should allow a precise understanding of the relationships among these various determinants on the surface of the molecule.
Summary
The HLA-A2-specific mouse monoclonal antibody BB7.2 plus complement has been used to immunoselect variant clones of the lymphoblastoid cell line T5-1 (HLA-A1, -A2, -Bg, and -B27). Members of one class of variant clones appear to express cell surface HLA-A2 molecules that display reduced reactivity with the selecting antibody, but normal or near normal reactivities with some other HLA-A2-specific monoclonal antibodies and human alloantisera. The HLA-A2 heavy chains derived from two of these variant clones were characterized by comparative double-label tryptic peptide mapping in conjunction with microsequence analysis. These heavy chains were found to carry distinct mutations in the same peptide in the molecule. We conclude that residues within this short segment of the polypeptide contribute to an HLA-A2-specific serological determinant.
